Real-World check: ivacaftor holds up for cystic fibrosis patients

This study looked at how well the drug Ivacaftor works and how safe it is for people with cystic fibrosis who have a specific genetic change (G551D mutation) in everyday life, not just in a controlled trial. Researchers followed 57 French patients aged 6 and older for one year after the drug was approved. They measured lung function, hospital stays, and antibiotic use to see if the benefits seen in earlier studies continue in real-world settings.